{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:56:25Z","timestamp":1791510985923,"version":"4.3.4"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:00:00Z","timestamp":1676073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ajpc.2023.100472","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T18:58:23Z","timestamp":1677524303000},"page":"100472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the National Lipid Association and the American Society for Preventive Cardiology"],"prefix":"10.1016","volume":"13","author":[{"given":"Salim S.","family":"Virani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Aspry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave L.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith C.","family":"Ferdinand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice L.","family":"McAlister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Neff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpc.2023.100472_bib0001","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics-2022 update: a report from the American heart association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2023.100472_bib0002","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.jacc.2022.02.048","article-title":"High-intensity statin use among patients with atherosclerosis in the U.S","volume":"79","author":"Nelson","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2023.100472_bib0003","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics\u20142023 update: a report from the American heart association","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2023.100472_bib0004","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1001\/archinte.1992.00400190110021","article-title":"Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial","volume":"152","author":"Neaton","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ajpc.2023.100472_bib0005","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Cholesterol treatment trialists' (CTT) collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2023.100472_bib0006","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2023.100472_bib0007","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people","volume":"383","author":"Rapsomaniki","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2023.100472_bib0008","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.ajpc.2023.100472_bib0009","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2023.100472_bib0010","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/CIRCULATIONAHA.109.192703","article-title":"Defining and setting national goals for cardiovascular health promotion and disease reduction: the American heart association\u2019s strategic impact goal through 2020 and beyond","volume":"121","author":"Lloyd-Jones","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2023.100472_bib0011","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Cholesterol treatment trialists' (CTT) collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2023.100472_bib0012","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jamacardio.2017.1421","article-title":"Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis","volume":"2","author":"Bundy","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ajpc.2023.100472_bib0013","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2023.100472_bib0014","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(14)61212-5","article-title":"Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data","volume":"384","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2023.100472_bib0015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2023.100472_bib0016","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the cholesterol treatment trialists collaboration","volume":"39","author":"Ference","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajpc.2023.100472_bib0017","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2023.100472_bib0018","unstructured":"National Committee for Quality Assurance. Statin therapy for patients with cardiovascular disease and diabetes (SPC\/SPD). https:\/\/www.ncqa.org\/hedis\/measures\/statin-therapy-for-patients-with-cardiovascular-disease-and-diabetes\/. Accessed 21 November 2022."},{"key":"10.1016\/j.ajpc.2023.100472_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.004652","article-title":"Variation in lipid-lowering therapy use in patients with low-density lipoprotein cholesterol \u2265190\u00a0mg\/dl: insights from the national cardiovascular data registry\u2212practice innovation and clinical excellence registry","volume":"11","author":"Virani","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ajpc.2023.100472_bib0020","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","article-title":"Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction","volume":"69","author":"Serban","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2023.100472_bib0021","first-page":"19","article-title":"Overcoming barriers to statin adherence","volume":"44","author":"Bui","year":"2019","journal-title":"US Pharm"},{"key":"10.1016\/j.ajpc.2023.100472_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2016.10.003","article-title":"Clinical and economic consequences of statin intolerance in the United States: results from an integrated health system","volume":"11","author":"Graham","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajpc.2023.100472_bib0023","article-title":"Factors associated with disparities in appropriate statin therapy in an outpatient inner city population","volume":"8","author":"Suero-Abreu","year":"2020","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.ajpc.2023.100472_bib0024","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.amjcard.2021.08.070","article-title":"Gaps and disparities in primary prevention statin prescription during outpatient care","volume":"161","author":"Metser","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ajpc.2023.100472_bib0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2017.10.006","article-title":"Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry","volume":"267","author":"Amrock","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ajpc.2023.100472_bib0026","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.1129","article-title":"Association of socioeconomic status with risk factor target achievements and use of secondary prevention after myocardial infarction","volume":"4","author":"Ohm","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ajpc.2023.100472_bib0027","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1007\/s13300-021-01115-w","article-title":"Impact of socioeconomic factors and gender on refill adherence and persistence to lipid-lowering therapy in type 1 diabetes","volume":"12","author":"Hero","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ajpc.2023.100472_bib0028","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2215539","article-title":"Aligning quality measures across CMS\u2014The universal foundation","author":"Jacobs","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2023.100472_bib0029","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2023.100472_bib0030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jama.283.1.94","article-title":"Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease","volume":"283","author":"Lee","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2023.100472_bib0031","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2023.100472_bib0032","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American heart association\/American stroke association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.ajpc.2023.100472_bib0033","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jacc.2015.02.003","article-title":"2015 ACC\/AHA focused update of secondary prevention lipid performance measures: a report of the American college of cardiology\/American heart association task force on performance measures","volume":"67","author":"Drozda","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2023.100472_bib0034","doi-asserted-by":"crossref","DOI":"10.1161\/HCQ.0000000000000032","article-title":"2017 AHA\/ACC clinical performance and quality measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American college of cardiology\/American heart association task force on performance measures","volume":"10","author":"Jneid","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ajpc.2023.100472_bib0035","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2023.100472_bib0036","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2023.100472_bib0037","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2023.100472_bib0038","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American college of cardiology solution set oversight committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2023.100472_bib0039","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","article-title":"Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajpc.2023.100472_bib0040","unstructured":"National Committee for Quality Assurance. HEDIS MY 2022: measures and descriptions. https:\/\/www.ncqa.org\/wp-content\/uploads\/2021\/12\/HEDIS-MY-2022-Measure-Descriptions.pdf. Accessed 27 October 2022."},{"key":"10.1016\/j.ajpc.2023.100472_bib0041","unstructured":"Centers for Medicare & Medicaid Services. 2022 CMS web interface. PREV-13: statin therapy for the prevention and treatment of cardiovascular disease. https:\/\/qpp.cms.gov\/docs\/QPP_quality_measure_specifications\/Web-Interface-Measures\/2022_Measure_PREV13_CMSWebInterface_v6.0.pdf. Accessed 27 October 2022."},{"key":"10.1016\/j.ajpc.2023.100472_bib0042","unstructured":"National Committee for Quality Assurance. 2023 Health plan ratings required HEDIS\u00ae, CAHPS\u00ae and HOS measures. https:\/\/www.ncqa.org\/wp-content\/uploads\/2022\/04\/2023-HPR-List-of-Required-Performance-Measures_4.25.2022.pdf. Accessed."},{"key":"10.1016\/j.ajpc.2023.100472_bib0043","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10557-020-07057-y","article-title":"Statin prescription rates, adherence, and associated clinical outcomes among women with PAD and ICVD","volume":"34","author":"Mahtta","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ajpc.2023.100472_bib0044","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.11051","article-title":"Evaluation of aspirin and statin therapy use and adherence in patients with premature atherosclerotic cardiovascular disease","volume":"3","author":"Mahtta","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ajpc.2023.100472_bib0045","first-page":"574","article-title":"Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis","volume":"28","author":"Lemstra","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ajpc.2023.100472_bib0046","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/ehjqcco\/qcab024","article-title":"High-statin adherence over 5 years of follow-up is associated with improved cardiovascular outcomes in patients with atherosclerotic cardiovascular disease: results from the IMPRES study","volume":"8","author":"May","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.ajpc.2023.100472_bib0047","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamacardio.2018.4936","article-title":"Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease","volume":"4","author":"Rodriguez","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ajpc.2023.100472_bib0048","doi-asserted-by":"crossref","first-page":"580","DOI":"10.7326\/0003-4819-157-8-201210160-00013","article-title":"Rethinking adherence","volume":"157","author":"Steiner","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajpc.2023.100472_bib0049","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/j.amjmed.2019.04.002","article-title":"Association between lipid testing and statin adherence in the veterans affairs health system","volume":"132","author":"Jia","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.ajpc.2023.100472_bib0050","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.amjmed.2021.11.011","article-title":"Association of low-density lipoprotein testing after an atherosclerotic cardiovascular event with subsequent statin adherence and intensification","volume":"135","author":"Rana","year":"2022","journal-title":"Am J Med"},{"key":"10.1016\/j.ajpc.2023.100472_bib0051","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HCR.0b013e318235c729","article-title":"Adherence behavior in the prevention and treatment of cardiovascular disease","volume":"32","author":"Miller","year":"2012","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"10.1016\/j.ajpc.2023.100472_bib0052","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1177\/1559827617729634","article-title":"Goal setting and action planning for health behavior change","volume":"13","author":"Bailey","year":"2019","journal-title":"Am J Lifestyle Med"},{"key":"10.1016\/j.ajpc.2023.100472_bib0053","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jacl.2013.10.004","article-title":"Effect of health information technology interventions on lipid management in clinical practice: a systematic review of randomized controlled trials","volume":"7","author":"Aspry","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajpc.2023.100472_bib0054","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jacc.2019.08.014","article-title":"Therapeutic inertia in cardiovascular disease prevention: time to move the bar","volume":"74","author":"Dixon","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2023.100472_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2011.07.013","article-title":"Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease","volume":"162","author":"Virani","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.ajpc.2023.100472_bib0056","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jacl.2022.05.003","article-title":"Adherence to lipid monitoring and its impact on treat intensification of LDL-C lowering therapies at an urban academic medical center","volume":"16","author":"Tran","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajpc.2023.100472_bib0057","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jacl.2013.10.002","article-title":"Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshop","volume":"7","author":"Cohen","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajpc.2023.100472_bib0058","article-title":"Kaiser Permanente: bridging the quality divide with integrated practice, group accountability, and health information technology","author":"McCarthy","year":"2009","journal-title":"The Commonwealth Fund publication 1278"},{"key":"10.1016\/j.ajpc.2023.100472_bib0059","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014415","article-title":"Cumulative adherence to secondary prevention guidelines and mortality after acute myocardial infarction","volume":"9","author":"Solomon","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2023.100472_bib0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.165.1.49","article-title":"Clinical pharmacy cardiac risk service study group. Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization","volume":"165","author":"Olson","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ajpc.2023.100472_bib0061","doi-asserted-by":"crossref","first-page":"4","DOI":"10.7812\/TPP\/08-007","article-title":"Collaborative cardiac care service: a multidisciplinary approach to caring for patients with coronary artery disease","volume":"12","author":"Sandhoff","year":"2008","journal-title":"Perm J"},{"key":"10.1016\/j.ajpc.2023.100472_bib0062","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1001\/jamacardio.2022.4018","article-title":"Results of a remotely delivered hypertension and lipid program in more than 10\u00a0000 patients across a diverse health care network","volume":"8","author":"Blood","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ajpc.2023.100472_bib0063","doi-asserted-by":"crossref","first-page":"C192","DOI":"10.1093\/eurheartj\/suac012.344","article-title":"The management of cholesterol level controlwith lipid-lowering drugs in Italian clinical practice: findings from the STREAM (Supporting with the real-world evidence the assessment of medicines and health technologies) study (abstract; P357)","volume":"24","author":"Degli Esposti","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajpc.2023.100472_bib0064","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.020890","article-title":"Racial disparities in modifiable risk factors and statin usage in black patients with familial hypercholesterolemia","volume":"10","author":"Agarwala","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2023.100472_bib0065","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Cholesterol treatment trialists' (CTT) collaboration. efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2023.100472_bib0066","first-page":"e10965","article-title":"Statins versus proprotein convertase subtilisin\/kexin type 9 inhibitors- are we doing better? A systematic review on treatment disparity","volume":"12","author":"Singh","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.ajpc.2023.100472_bib0067","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005562","article-title":"Sex differences in the use of statins in community practice","volume":"12","author":"Nanna","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ajpc.2023.100472_bib0068","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1161\/CIR.0b013e3181f7d78c","article-title":"ACCF\/AHA new insights into the methodology of performance measurement: a report of the American college of cardiology foundation\/American heart association task force on performance measures","volume":"122","author":"Spertus","year":"2010","journal-title":"Circulation"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667723000144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667723000144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:39:13Z","timestamp":1763005153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667723000144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":68,"alternative-id":["S2666667723000144"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2023.100472","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the National Lipid Association and the American Society for Preventive Cardiology","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2023.100472","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100472"}}